Feb 19, 2026 5:46 pm EST Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
Feb 5, 2026 7:00 am EST Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
Jan 11, 2026 4:00 pm EST Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
Dec 19, 2025 7:00 am EST Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 17, 2025 7:00 am EST Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
Dec 12, 2025 7:00 am EST Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
Dec 9, 2025 7:00 am EST Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
Nov 17, 2025 7:00 am EST Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
Nov 14, 2025 7:00 am EST New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
Nov 11, 2025 7:00 am EST Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
